Abstracts tagged "gout"

Abstract Number: 0049 • ACR Convergence 2023
Soluble Uric Acid Is an Endogenous Inhibitor of CD38
Shijie Wen¹, Hiroshi Arakawa¹, Shigeru Yokoyama², Yoshiyuki Shirasaka¹, Haruhiro Higashida³ and Ikumi Tamai¹, ¹Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan, ²Research Center for Child Mental Development, Kanazawa University; Division of Socio-Cognitive-Neuroscience, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Kanazawa University, Kanazawa, Japan, ³Research Center for Child Mental Development, Kanazawa University, Kanazawa, Japan
Background/Purpose: CD38 is the main NAD+-degrading enzyme that plays a key role in innate immunity, aging, cancer, and metabolic disorders. Pharmacological inhibition of CD38 has…
Abstract Number: 0245 • ACR Convergence 2023
Impact of Combined Intervention with Clinical Nurse Specialist in the Management of Cardiovascular Risk in Patients with Gout
Claudia Maria Gomez¹, Patricio Cardoso Peñafiel¹, Jose Antonio Angel-Sesmero¹, Marta Novella-Navarro² and Enrique Calvo-Aranda¹, ¹Hospital Universitario Infanta Leonor, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Gout is associated with increased cardiovascular risk (CVR). Traditional CVR factors (CVRF) are frequently present in patients with gout, further worsening the prognosis. Several…
Abstract Number: 1037 • ACR Convergence 2023
Dual Energy Computed Tomography (DECT) Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Intensive Urate-Lowering Therapy
Adwoa Dansoa Tabi-Amponsah¹, Sarah Stewart², Greg Gamble¹, Anthony Doyle³, Chang-Nam Son⁴, Kieran Latto¹, Lisa Stamp⁵, William Taylor⁶, Anne Horne¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Auckland University of Technology, Auckland, New Zealand, ³Auckland District Health Board and University of Auckland, Auckland, New Zealand, ⁴Uijeongbu Eulji Medical Center, Eulji University School of Medicine, UIJEONGBU, South Korea, ⁵University of Otago, Christchurch, New Zealand, ⁶University of Otago, Wellington, New Zealand
Background/Purpose: Preliminary gout remission criteria have been developed using OMERACT core outcome domains for long-term gout studies. This study aimed to identify variables that predict…
Abstract Number: 1121 • ACR Convergence 2023
Cardiovascular Safety of Febuxostat in Patients with Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials
Roba Ghossan¹, Ouidade Aitisha Tabesh², Fouad Fayad², Pascal Richette³ and Thomas Bardin⁴, ¹COCHIN HOSPITAL, Paris, France, ²Hotel Dieu de France, Beirut, Lebanon, ³Lariboisière Hospital, Paris, France, ⁴Université de Paris Cité, Paris, France
Background/Purpose: To this date, a causal relationship between febuxostat and cardiovascular disease remains controversial as comparison between trials can be challenging and may lead to…
Abstract Number: 0058 • ACR Convergence 2023
Macrophage Extracellular Traps Induced by Monosodium Urate or Calcium Pyrophosphate Crystals Form Independently of NLRP3 Inflammasome Activation
Douglas Daoudlarian¹, André Tiaden², Stavros Giaglis³, Ulrich Walker⁴, Petr Broz⁵, Tobias Maningold⁶ and Diego Kyburz¹, ¹University Hospital Basel, Basel, Switzerland, ²Laboratory for Experimental Rheumatology, Department of Biomedicine, University of Basel, Basel, Switzerland, ³University of Basel/University Hospital of Basel, Basel, Switzerland, ⁴Basel University Hospital, Basel, Switzerland, ⁵University of Lausanne, Lausanne, Switzerland, ⁶Department of Rheumatology, University Hospital Bern (Inselspital), University Bern, Bern, Switzerland
Background/Purpose: Monosodium urate (MSU) and calcium pyrophosphate (CPP) crystals are potent inducers of inflammation by activation of the inflammasome in neutrophils phagocytosing the crystals and…
Abstract Number: 0246 • ACR Convergence 2023
Safety & Efficacy of SEL-212 in Patients with Gout Refractory to Conventional Treatment: Primary Outcomes from Two Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Studies
Herbert Baraf¹, Alan Kivitz², Sheri Rhodes³, Sheldon Leung⁴, Olu Folarin⁴, Tania Gonzalez-Rivera⁵, Joanna Sobierska⁵, Jacquie Christie⁵, Anand Patel⁶, Wesley DeHaan⁴, Rehan Azeem⁴ and Peter Traber⁷, ¹The Center for Rheumatology and Bone Research, George Washington University, Rheumatology, Bethesda, MD, ²Altoona Center for Clinical Research, Duncansville, PA, ³Selecta Biosciences, Atlanta, GA, ⁴Selecta Biosciences, Inc., Watertown, MA, ⁵Swedish Orphan Biovitrum (Sobi), Stockholm, Sweden, ⁶Pioneer Research Solutions, Houston, TX, ⁷Selecta Biosciences, Gladwyne, PA
Background/Purpose: In patients with refractory gout, the inability to maintain serum uric acid (sUA) levels < 6 mg/dL leads to severe clinical manifestations for which…
Abstract Number: 1102 • ACR Convergence 2023
Finding Lost-to-Care Gout Patients in a Large Community Rheumatology Network: Patient Re-engagement Initiative with Metrics (PRIME)
Amy S. Mudano¹, Jessica Ryan¹, Emily Holladay², Kathleen Methric³, Danielle Grauer⁴, Brian LaMoreaux³, Fenglong Xie¹ and Jeffrey R Curtis⁵, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Horizon Therapeutics, Deerfield, IL, ⁴Illumination Health, Boca Raton, FL, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: Treatment of patients with gout can be complex and, given the episodic nature of gout attacks, gout patients may not always return for regular…
Abstract Number: 1122 • ACR Convergence 2023
The Tophus Impact Questionnaire (TIQ-20): Responsiveness to Change During Urate-Lowering Therapy
Cindy Cao¹, Greg Gamble¹, Anne Horne¹, Opetaia Aati¹, Anthony Doyle¹, Jill Drake², Lisa Stamp³ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Te Whatu Ora Waitaha, Christchurch, New Zealand, ³University of Otago, Christchurch, New Zealand
Background/Purpose: In 2015, the 20-item Tophus Impact Questionnaire (TIQ-20) was developed as a tophus-specific patient reported outcome measure (Aati et al., 2015). Initial analysis of…
Abstract Number: 0229 • ACR Convergence 2023
Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout
HYUNSUE DO and Kiwon Moon, Kangwon National University Hospital, Seoul, South Korea
Background/Purpose: Gout, which is a prevalent form of inflammatory arthritis, is generally considered to be more effectively managed through medication. Besides of maintaining medication, they…
Abstract Number: 0247 • ACR Convergence 2023
Risk of Incident Gout Following Exposure to Recombinant Zoster Vaccine in Adults Aged ≥50 Years in the United States
Sheryl Kluberg¹, Andrew Simon², Sarah Alam², Alexander Peters², Casie Horgan², Dongdong Li², Érick Moyneur³, Richard Platt², Cheryl N McMahill-Walraven⁴, Djeneba Audrey Djibo⁴, Qianli Ma⁵, Mano Selvan⁵, Claire Pernar⁶, Najat Ziyadeh⁶, Aziza Jamal-Allial⁷, Kimberly Daniels⁷, O’Mareen Spence⁸, Driss Oraichi⁸, Harry Seifert⁸, Valentine Franck⁹, Susan Gamble⁸ and Huifeng Yun⁸, ¹Harvard Medical School and Harvard Pilgrim Health Care Institute, Newton, MA, ²Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, ³StatLog Inc, Quebec City, QC, Canada, ⁴CVS Health, Blue Bell, PA, ⁵Humana Healthcare Research, Inc., Louisville, KY, ⁶Optum, Baltimore, MD, ⁷Carelon Research, Boston, MA, ⁸GlaxoSmithKline, Rockville, MD, ⁹GlaxoSmithKline, Wavre, Belgium
Background/Purpose: Pre-licensure clinical trials for recombinant zoster vaccine (RZV) identified more frequent gout diagnoses among recipients of RZV than placebo; however, these trials were not…
Abstract Number: 1103 • ACR Convergence 2023
Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy
Emily Holladay¹, Amy S. Mudano², Fenglong Xie², Jingyi Zhang¹, Ted R Mikuls³, Brian LaMoreaux⁴, Lissa Padnick-Silver⁴ and Jeffrey Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Illumination Health, Hoover, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴Horizon Therapeutics, Deerfield, IL
Background/Purpose: Little is known about the long-term effects of pegloticase therapy or what urate-lowering therapy (ULT) patients subsequently receive when they discontinue pegloticase. This analysis…
Abstract Number: 1123 • ACR Convergence 2023
Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016
John Botson¹, Qianhong Fu², Kaiding Zhu², Lissa Padnick-Silver² and Brian LaMoreaux², ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase can treat uncontrolled gout but anti-drug antibodies limit urate-lowering response and put patients at risk for infusion reactions (IRs).1, 2 The first case…
Abstract Number: 0231 • ACR Convergence 2023
Febuxostat Dose Requirement for Achieving Target Serum Urate Levels According to Renal Function: A Retrospective Cohort Study
YoungEun Kim¹, Hansun Song¹, Wook Jang Seo², Jinseok Kim³, Soo Min Ahn¹, Ji-Seon Oh⁴, Yong-Gil Kim¹, Chang-Keun Lee⁵, Bin Yoo⁵ and Seokchan Hong⁶, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ²Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea, ³Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, ⁴Department of Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea, ⁵Asan Medical Center, Seoul, South Korea, ⁶Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background/Purpose: Febuxostat clearance is not affected by kidney function, and the risk of adverse events from allopurinol, including fatal hypersensitivity reactions, is higher in patients…
Abstract Number: 0248 • ACR Convergence 2023
In-hospital Treatment, Secondary Prevention, and Mortality After First-ever Acute Myocardial Infarction in Patients with Gout
Panagiota Drivelegka¹, Lennart Jacobsson², Tatiana Zverkova-Sandström³ and Mats Dehlin⁴, ¹Department of Rheumatology, Sahlgrenska University hospital, Gothenburg, Sweden, ²University of Gothenburg, Malmö, Sweden, ³Institution of Medicine, Gothenburg, Sweden, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Patients with gout are at increased risk of acute myocardial infarction (AMI). However, the clinical course, secondary prophylaxis and mortality after AMI has not…
Abstract Number: 1104 • ACR Convergence 2023
Dotinurad, a Potent and Selective Uricosuric Agent, Exhibited Promising Pharmacokinetics and Pharmacodynamic Profiles to Significantly Reduce Serum Urate Levels Following Once Daily Dosing in Healthy U.S. Subjects in a Phase 1 Clinical Trial
Scott Baumgartner, Raymond Zheng, Mark Harnett and Jay Kranzler, Urica Therapeutics Inc., New York, NY
Background/Purpose: Dotinurad is a potent and selective URAT1 inhibitor that has been approved as a once-daily drug for the treatment of hyperuricemia with or without…

« Previous Page
1
…
6
7
8
9
10
…
45
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].